In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Logicbio Therapeutics (LOGC – Research Report), with a price target of $20.00. The company’s shares closed last Monday at $3.89, close to its 52-week low of $3.72.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 68.0% and a 58.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
Logicbio Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.33.
See the top stocks recommended by analysts >>
The company has a one-year high of $9.75 and a one-year low of $3.72. Currently, Logicbio Therapeutics has an average volume of 84.55K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Read More on LOGC:
